Literature DB >> 22902420

Use of prescribed optical devices in age-related macular degeneration.

Dawn K Decarlo1, Gerald McGwin, Karen Searcey, Liyan Gao, Marsha Snow, Lynne Stevens, Cynthia Owsley.   

Abstract

PURPOSE: To evaluate prescribed optical device use in terms of frequency and perceived usefulness among people with age-related macular degeneration (AMD). We also sought to determine the tasks for which they were using their prescribed low vision device(s).
METHODS: One hundred ninety-nine patients with AMD presenting for the first time to the low vision service were recruited from a university-based clinic. Prior to the low vision evaluation and device prescription, they completed the National Eye Institute Visual Function Questionnaire 25, Center for Epidemiological Studies Depression Scale, Short Portable Mental Status Questionnaire, and a general health questionnaire. The low vision evaluation included best-corrected Early Treatment of Diabetic Retinopathy Study visual acuity, MNREAD testing, microperimetry, prescription, and dispensing of optical low vision devices. Telephone follow-up interviews were conducted about device usage 1-week, 1-month, and 3-months postintervention.
RESULTS: One hundred eighty-one participants were prescribed low vision devices. Of them, 93% completed all 3 follow-up interviews. Intensive users (≥1 hours/day) of devices were similar in demographic and visual characteristics to non-intensive users (<1 hours/day), except for habitual reading acuity and speed as well as contrast sensitivity. Overall, device use increased slightly over 3 months of follow-up. Magnifiers were reported to be moderately-to-extremely useful by >80% of participants at all time points except the 1-month follow-up for hand magnifiers (75%). High plus spectacles were the least frequently prescribed device and rated as moderately-to-extremely useful by 70%, 74%, and 59% at 1 week, 1 month, and 3 months, respectively. Most participants used their devices for leisure reading, followed by managing bills. Very few devices (n = 3, <1%) were not used at any time point.
CONCLUSIONS: Patients with AMD who are provided with prescribed optical low vision devices do use them and perceive them as useful, especially for leisure reading activities. High rates of usage were maintained over 3 month.

Entities:  

Mesh:

Year:  2012        PMID: 22902420      PMCID: PMC3474350          DOI: 10.1097/OPX.0b013e3182678db5

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  28 in total

1.  Development of the 25-item National Eye Institute Visual Function Questionnaire.

Authors:  C M Mangione; P P Lee; P R Gutierrez; K Spritzer; S Berry; R D Hays
Journal:  Arch Ophthalmol       Date:  2001-07

2.  Abandonment of low-vision devices in an outpatient population.

Authors:  Bradley E Dougherty; K Bradley Kehler; Richard Jamara; Nicole Patterson; Denise Valenti; Fuensanta A Vera-Diaz
Journal:  Optom Vis Sci       Date:  2011-11       Impact factor: 1.973

3.  A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients.

Authors:  E Pfeiffer
Journal:  J Am Geriatr Soc       Date:  1975-10       Impact factor: 5.562

4.  Psychological and cognitive determinants of vision function in age-related macular degeneration.

Authors:  Barry W Rovner; Robin J Casten; Robert W Massof; Benjamin E Leiby; William S Tasman
Journal:  Arch Ophthalmol       Date:  2011-07

5.  Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration.

Authors:  B L Brody; A C Gamst; R A Williams; A R Smith; P W Lau; D Dolnak; M H Rapaport; R M Kaplan; S I Brown
Journal:  Ophthalmology       Date:  2001-10       Impact factor: 12.079

6.  Enhanced low vision rehabilitation for people with age related macular degeneration: a randomised controlled trial.

Authors:  B C Reeves; R A Harper; W B Russell
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

7.  Vision-specific health-related quality of life in age-related maculopathy patients presenting for low vision services.

Authors:  Kay Scilley; Dawn K DeCarlo; Jennifer Wells; Cynthia Owsley
Journal:  Ophthalmic Epidemiol       Date:  2004-04       Impact factor: 1.648

8.  Effect of depression on vision function in age-related macular degeneration.

Authors:  Barry W Rovner; Robin J Casten; William S Tasman
Journal:  Arch Ophthalmol       Date:  2002-08

9.  Impact of cataract surgery on motor vehicle crash involvement by older adults.

Authors:  Cynthia Owsley; Gerald McGwin; Michael Sloane; Jennifer Wells; Beth T Stalvey; Scott Gauthreaux
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

10.  Driving habits and health-related quality of life in patients with age-related maculopathy.

Authors:  Dawn K DeCarlo; Kay Scilley; Jennifer Wells; Cynthia Owsley
Journal:  Optom Vis Sci       Date:  2003-03       Impact factor: 1.973

View more
  5 in total

1.  [Requirements for low vision magnification aids in age-related macular degeneration: Data from the Tübingen low vision clinic (comparison of 2007-2011 with 1999-2005)].

Authors:  E K Altpeter; N X Nguyen
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

2.  Utilization and Abandonment of Low Vision Devices Prescribed on a Mobile Clinic.

Authors:  Micaela R Gobeille; Alexis G Malkin; Richard Jamara; Nicole C Ross
Journal:  Optom Vis Sci       Date:  2018-09       Impact factor: 1.973

Review 3.  Reading charts in ophthalmology.

Authors:  W Radner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-14       Impact factor: 3.117

4.  Implantation of Scharioth macula lens in patients with age-related macular degeneration: results of a prospective European multicentre clinical trial.

Authors:  Sathish Srinivasan
Journal:  BMJ Open Ophthalmol       Date:  2019-07-07

5.  Repeatability and Validity of MNREAD Test in Children With Vision Impairment.

Authors:  Dawn K DeCarlo; Liyan Gao; Gerald McGwin; Cynthia Owsley; MiYoung Kwon
Journal:  Transl Vis Sci Technol       Date:  2020-12-16       Impact factor: 3.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.